Vetnique Labs, a leading pet health and wellness company, has finalized the acquisition of Lintbells, renowned for its YuMOVE brand of pet supplements. This strategic move, facilitated by Gryphon Investors and expected to conclude in the third quarter of 2024, aims to enhance Gryphon’s footprint in the pet health sector.
YuMOVE, originating from Hertfordshire, UK, specializes in scientifically backed supplements catering to joint mobility for dogs and cats, alongside solutions for digestive health, anxiety, dermatological, and dental needs. As a certified B Corporation, YuMOVE emphasizes quality and efficacy in addressing chronic pet health conditions.
Vetnique Labs, recognized for its vet-formulated products such as Glandex, a leading treatment for anal gland disease in North America, shares YuMOVE’s commitment to veterinary-endorsed solutions. This acquisition underscores Gryphon’s strategy to expand its presence across key global markets, particularly in the U.S. and the UK.
Chris Slager, executive chairman of the combined entity, expressed enthusiasm about the merger’s potential. “Uniting these prominent brands allows us to scale significantly in critical areas like joint health and digestive wellness,” Slager noted. The consolidation aims to leverage Gryphon’s resources to introduce innovative, patented products to pet owners worldwide.
Under the leadership of James Bascharon, DVM, Vetnique will oversee operations in North America, while Fiona Hope continues as CEO of YuMOVE, managing operations across Europe and other regions. Dr. Bascharon emphasized the strategic alignment with Gryphon to accelerate YuMOVE’s growth in North America’s $3 billion supplement market.
Fiona Hope highlighted the partnership’s potential to drive global expansion and enhance pet quality of life. “Joining forces with Vetnique opens new avenues for global growth and innovation,” Hope stated, underscoring their shared vision to advance pet health and wellness on an international scale.
Related Topics:
